Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The White House announced the first batch of negotiated Medicare drug prices in August after negotiating for reduced prices for months. The 10 new lower prices — which ranged from a price cut of 79% for Type 2 diabetes drug Januvia to a 38% cut for cancer drug Imbruvica — will go into effect in January 2026.